DOI:
10.1055/s-00000058
Planta Medica
LinksClose Window
References
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S. FUTURE 2 Study Group.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet 2015;
386: 1137-1146
We do not assume any responsibility for the contents of the web pages of other providers.